GlassScriptPhysician profile
Kimberly C Thompson
NPI 1144892407
$62,458.52
in general payments reported to CMS, 2019-2025
12 companies · $6,948 in 2025
The $6,948 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $455 · 2022: $4,118 · 2023: $19K · 2024: $32K · 2025: $6,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $13K · Consulting Fee: $7,583 · Food and Beverage: $5,354 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,570.00 |
| Travel and Lodging | $13,188.28 |
| Consulting Fee | $7,582.50 |
| Food and Beverage | $5,353.61 |
| Education | $191.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $29,706.27 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $29,017.83 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Merck Sharp & Dohme LLC | $3,245.01 | 2024-2025 | Winrevair, Verquvo |
| Johnson & Johnson Health Care Systems INC. | $131.00 | 2023-2024 | Opsumit |
| Kerecis Limited | $91.94 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Bayer Healthcare Pharmaceuticals INC. | $75.47 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $57.30 | 2024 | Purified Cortrophin Gel |
| Cvrx, INC. | $54.39 | 2025 | Barostim Neo System |
| Sandoz INC. | $28.65 | 2024 | Treprostinil |
| Novartis Pharmaceuticals Corporation | $23.45 | 2023 | |
| Scpharmaceuticals INC. | $16.06 | 2025 | |
| Janssen Pharmaceuticals, INC | $11.15 | 2024 | Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.